SCI Pharmtech Inc
TWSE:4119
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
86.4
100
|
Price Target |
|
We'll email you a reminder when the closing price reaches TWD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
SCI Pharmtech Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | TW |
Market Cap | 11.7B TWD |
Net Margin |
11%
|
Country | JP |
Market Cap | 776 550.9T JPY |
Net Margin |
-79%
|
Country | US |
Market Cap | 710.5B USD |
Net Margin |
20%
|
Country | UK |
Market Cap | 440.4B GBP |
Net Margin |
-4%
|
Country | DK |
Market Cap | 3.3T DKK |
Net Margin |
35%
|
Country | US |
Market Cap | 373.5B USD |
Net Margin |
17%
|
Country | US |
Market Cap | 251.1B USD |
Net Margin |
19%
|
Country | CH |
Market Cap | 202.7B CHF |
Net Margin |
20%
|
Country | CH |
Market Cap | 183.3B CHF |
Net Margin |
35%
|
Country | UK |
Market Cap | 162.4B GBP |
Net Margin |
13%
|
Country | IE |
Market Cap | 146B USD |
Net Margin |
-126%
|
SCI Pharmtech Inc
Glance View
SCI Pharmtech Corp. is engaged in the biotechnology and medical care industry. The company is headquartered in Taoyuan, Taoyuan. The company went IPO on 2002-08-12. The firm's main products include APIs, API intermediates and special and precision chemicals. The firm distributes its products in domestic market and to overseas markets, including Europe, the Americas, the rest areas of Asia and others
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on SCI Pharmtech Inc's most recent financial statements, the company has Net Margin of 11.1%.